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SUMMARY 
We conducted a survey among Italian HIV specialists to study the utilization of statins and aspirin, 
administering a questionnaire aimed at investigating their use, the use of guidelines and scores, and 
the management of interactions.  
The answers were uniform in the different geographic areas. The majority directly prescribe statins 
and 43% of them prescribe aspirin. The majority follows guidelines and utilize scores to calculate the 
CV risk.  
Our survey demonstrates the commitment and autonomy in prescribing statins and aspirin of Italian 
physicians. There is a rationale to generate guidelines to overcome the differences and limitations 
among current recommendations.  
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The introduction of combined antiretroviral therapy (cART) regimens has had a major impact on the 
natural history of HIV infection, leading to a dramatic decrease in its mortality and a considerable 
increase in the life expectancy of people living with HIV (PLWHIV). Nevertheless, these patients 
still appear to be at higher risk of a number of co-morbidities, such as CVD, than the general 
population (Nou et al., 2016; Martin-Iguacel et al., 2015; Freiberg et al., 2013). The etiology of the 
increased risk is still not completely understood, but endothelial activation due to the chronic 
inflammation may play a pivotal role in CVD events (Durand et al., 2011). Statins and aspirin have 
a pivotal role in reducing the morbidity and mortality of CVD. The effect of statins and aspirin in 
preventing CVD is linked to their anti-inflammatory activity on vessels and, consequently there is a 
stronger rationale in their use among PLWHIV. However the current guidelines (The Task Force for 
the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European 
Atherosclerosis Society (EAS 2011; ACC/AHA, 2013) for the use of these drugs in the general 
population are dissimilar, with important differences between American and European 
recommendations, and the guidelines for PLWHIV reflect this scenario resulting sometimes 
incomplete. Regarding PLWHIV, the European AIDS Clinical Society (EACS) version 8, 
recommends the use of statin in patients with established CVD or type 2 diabetes or 10-year CVD 
risk ≥10 % irrespective of lipid levels. Similarly aspirin is recommended in patients with previous 
CVD or aged ≥50 years and at high (≥20 %) 10-year CVD risk (EACS guidelines, version 6.1; 2011). 
However, some reports emphasize the underutilization of aspirin in HIV patients and few data are 
available on use of statins and aspirin in such a setting in clinical practice (Tornero et al., 2010; 
Burkholder et al., 2012). Also, a recent Italian study found that the prescription of statins and aspirin 
in HIV-infected patients remains largely suboptimal, as only about 50% of patients requiring statins 
and aspirin are properly treated (De Socio et al., 2016). For this reason, we conducted a survey among 
Italian HIV specialists to investigate the use of these drugs in the real life setting and understand if 
there is the need for specifically addressed guidelines for HIV-positive patients. 
A self-administerd questionnaire was sent to all physicians committed to outpatient care and directly 
responsible for drug prescription (both antiretrovirals and co-administration therapies for HIV-
associated non-AIDS conditions) among 27 infectious disease units in Italy from November 2015 to 
January 2016. The questionnaire was based on the following ten points, investigating their use of 
statins and aspirin, the use of specific guidelines, scores and parameters driving their choices and the 
management of drug-drug interactions (DDIs).  
1) Do you directly prescribe/suggest statins in your PLWHIV when appropriate? The following 
answers were possible: a) Yes, b) No, I refer my patients to other specialists if I think they need statins 
c) No, I do not treat cardiovascular risk in my PLWHIV.   
 
 
2) Do you follow any guideline to evaluate the opportunity of prescribing statins in your PLWHIV? 
The following answers were possible: a) Yes, b) No.  
3) If yes, which one? The following answers were possible: a) EACS HIV, b) Italian HIV Guidelines, 
c) American College of Cardiology/American Heart Association (ACC/AHA) 2013. 
4) If not, how do you evaluate the opportunity of prescribing statins in your PLWHIV? The following 
answers were possible: a) Based on total cholesterol, b) Based on LDL-C, c) Based on estimated 
cardiovascular risk, d) In the presence of co-morbidity (e.g., diabetes).  
5) Do you directly prescribe/suggest aspirin in your HIV patients when appropriate? The following 
answers were possible: a) Yes, b) No, I refer my patients to other specialists if I think they need 
aspirin c) No, I do not treat cardiovascular risk in my PLWHIV.  
6) Do you utilize any score to calculate the cardiovascular risk of your PLWHIV? The following 
answers were possible: a) Yes, b) No, I evaluate the risk factors (blood pressure, cholesterol, smoke, 
diabetes) without the use of scores, c) No, I do not evaluate cardiovascular risk factors at all.  
7) If yes, which one? The following answers were possible: a) FRS, b) ASCVD, c) Data Collection 
on Adverse events of Anti-HIV Drugs (DAD), d) Progetto Cuore. 
8) Do you prescribe statins in patients with subclinical atherosclerosis diagnosed by coronary artery 
calcium (CAC) or intima-media thickness (IMT)? The following answers were possible: a) Yes, b) 
No.  
9) Before prescribing a statin do you evaluate the DDIs with antiretroviral therapy? The following 
answers were possible: a) Yes, b) No. 
10) In case of DDIs do you… The following answers were possible: a) Abandon the statin therapy? 
b) Change the statin? c) Consult a cardiologist? 
For the questions 3, 4 and 7 multiple answers were admitted. 
The participants were 128 Italian HIV physicians. All the physicians filled out the questionnaire. Of 
them 33 were from North, 43 from Central and 52 from South Italy. As shown in Table 1, 89% 
directly prescribe or suggest statins, while 43% prescribe or suggest aspirin. The remaining physicians 
refer the patient to other specialists. 73% follow guidelines for prescribing statins, mainly Italian 
guidelines (46%), followed by EACS-HIV (35%) and ACC/AHA 2013 (19%). Thoe who do not 
follow guidelines prescribe statins based on LDL-C (36%), estimated CV risk (34%), or presence of 
co-morbidities (21%), while total cholesterol is rarely used (9%). 58% utilize scores to calculate CV 
risk: the vast majority use FRS (71%) followed by DAD (12%), ASCVD (13%) while only 4% use 
 
 
Progetto Cuore; 50% prescribe statins also in case of subclinical atherosclerosis; 97% consider DDIs 
between statins and cART and, in case of DDIs, 49% change the statin, 38% consult the cardiologist 
and 13% abandon the statin. Table 1 also shows the differences between the three geographic areas.  
Results from several studies have suggested that PLWHIV have an increased risk of CVD, especially 
coronary heart disease, compared with people not infected with HIV. The incidence of CVD overall 
in HIV is relatively low, but it is approximately 1.5-2-fold higher than that seen in age-matched HIV-
uninfected individuals. PLWHIV are exposed both to an increased prevalence of traditional CVD risk 
factors, and to HIV-specific mechanisms such as inflammation (Nou et al., 2016; Martin-Iguacel et 
al., 2015). The early and continuous use of current cART, which might have fewer metabolic effects, 
minimizes the risk of myocardial infarction by maintaining viral suppression and decreasing immune 
activation. Even with cART, however, immune activation persists in PLWHIV and could contribute 
to accelerated atherosclerosis (Hsue et al., 2009; Calmy et al., 2009; Friis-Møller et al., 2010; 
Neuhaus et al., 2010; Durand et al., 2011; Hsue, 2012; Freiberg et al., 2013). Therefore, treatments 
that safely reduce inflammation in PLWHIV could provide additional cardiovascular protection 
alongside treatment of both traditional and non-traditional risk factors. 
About thirty years ago, statins ushered in the era of lipid lowering as the most effective way to reduce 
risk of atherosclerotic cardiovascular disease. More recently it has been demonstrated that statins, 
through their HMG-CoA reductase inhibitor activity, have pleiotropic immunomodulatory properties 
that contribute to their benefit in atherosclerosis beyond lipid lowering (Walter et al., 2002; Shapiro 
and Fazio, 2016). 
On the other hand, aspirin remains one of the most extensively studied cardiovascular medications in 
the history of medicine. The drug reduces the incidence of myocardial infarction (MI), stroke, and 
vascular death in patients with vascular disease via its antiplatelet activity. However, despite multiple, 
well-designed, large randomized controlled trials evaluating the potential of aspirin to prevent 
cardiovascular events in individuals without known CVD, the role of aspirin in primary prevention is 
currently unclear. The initial aspirin trials included largely low-risk individuals with primary 
outcomes mostly focused on MI and stroke, and showed a significant reduction in these CVD 
outcomes, especially MI. The more recently conducted trials have focused on older, higher CVD risk 
populations with high rates of lipid-lowering and antihypertensive medication use. These studies have 
used broader CVD outcomes as their primary end points and have failed to show a significant benefit 
of aspirin therapy in primary prevention. The exact reasons for the lack of efficacy in these recent 
trials are unclear but may be related to the low rate of atherothrombotic events relative to other CVD 
events in the populations studied (Miedema et al., 2016). The evidence supporting aspirin for 
 
 
secondary CV prevention in the general population is stronger: in high risk patients ASA reduces the 
yearly risk of serious vascular events (non-fatal myocardial infarction, non-fatal stroke, or vascular 
death) by about a quarter (Antithrombotic Trialists' Collaboration, 2002). However, nowadays aspirin 
is recommended in secondary CV prevention as well for men aged 45 to 79 years when the potential 
benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase 
in gastrointestinal hemorrhage and for women age 55 to 79 years when the potential benefit of a 
reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal 
hemorrhage (Maciosek et al., 2006; Mosca et al., 2007; US Preventive Services Task Force, 2009). 
For the use of statins in CVD prevention, the European Society of Cardiology (ESC) and the European 
Atherosclerosis Society (EAS) Guidelines for the management of dyslipidaemias (The Task Force 
for the management of dyslipidaemias of the ESC and the EAS, 2011) suggest evaluating the total 
CV risk of the subjects using European SCORE tables, identify the LDL-C target for that risk level, 
calculate the percentage reduction of LDL-C required to achieve that goal, and choose a statin that, 
on average, can provide this reduction. For these guidelines, since the response to statin treatment is 
variable, up-titration to reach the target is mandatory. If the statin cannot reach the goal, they suggest 
considering drug combinations. 
Unlike European guidelines, the ACC/AHA identified four statin benefit groups in which the 
potential for an atherosclerotic CVD (ASCVD) risk reduction benefit clearly exceeds the potential 
for adverse effects (1-individuals with clinical ASCVD; 2- individuals with primary elevations of 
LDL–C ≥190 mg/dL; 3-individuals 40 to 75 years of age with diabetes with LDL-C 70-189 mg/dL; 
4-individuals without clinical atherosclerotic CVD or diabetes who are 40 to 75 years of age with 
LDL-C 70-189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher), identified  high-
intensity and moderate-intensity statin therapy for use in secondary and primary prevention and 
suggested the appropriate intensity of statin therapy to reduce ASCVD risk in those most likely to 
benefit. On the other hand, this Expert Panel was unable to find evidence to support continued use of 
specific LDL–C and/or non-HDL–C treatment targets. Finally, this guideline recommends use of the 
new Pooled Cohort Equations to estimate 10-year ASCVD risk (ACC/AHA 2013). 
Some European authors took a stand against ACC/AHA guidelines, objecting that if generally 
adopted, they will result in an increase in the number of patients treated, potentially at considerable 
cost. Moreover, the new pooled mixed cohorts equation used to assess ASCVD risk has been 
validated in an American population, different from European countries, and requires more careful 
evaluation if applied in other contexts (Ray et al., 2014). In summary, the debate between American 
and European guidelines is still open.  
 
 
To the best of our knowledge, this is the first survey performed on HIV specialists on this topic. Due 
to the high number of participants it can be considered a representative sample. The answers were 
uniform in the three geographic areas and demonstrate a great commitment toward CVD co-
morbidity. In fact, the majority of physicians directly prescribe statins and 50% of them directly 
prescribe aspirin, the remainder consult a specialist. None declare they did not treat the CVD of their 
HIV patients (answers 1 and 5). The majority follow guidelines for statin prescription (mainly the 
Italian Guidelines, followed by EACS, but cardiologic guidelines ACC/AHA are not infrequently 
consulted). The physicians who declare they do not follow guidelines base their prescription mainly 
on evaluation of CVD risk and LD-Cc levels. The majority utilize scores to calculate the CV risk of 
their patients (mainly FRS followed by DAD). Also in this case, ASCVD cardiologic guidelines are 
not infrequently consulted. 50% of the physicians directly prescribe statins in case of subclinical 
atherosclerosis. The risk of DDIs with statins is widely considered. The majority of the Italian HIV 
specialists directly choose a different statin in case of DDIs.  
Some minor differences emerged comparing the three different geographic areas. Physicians in 
Southern Italy tend to refer patients to other specialists if they think they need statins or aspirin with 
respect to their colleagues in Northern and Central Italy, and evaluate the CV risk based on the single 
risk factors while their Northern and Southern colleagues use scores more frequently. Moreover, 
physicians in Southern Italy tend to utilize Italian guidelines more frequently while Northern and 
Center physicians prefer EACS guidelines and Central physicians frequently also consult the 
ACC/AHA.  
In conclusion, our survey demonstrates the high attention of Italian HIV physicians to CVD, and their 
commitment and autonomy in prescribing statins and aspirin. Consequently, in the light of the 
previously discussed discrepancies among the different guidelines and the incomplete indications 
regarding HIV-positive persons, there is a strong rationale to generate specific guidelines for HIV 
patients able to overcome the differences and limitations among current recommendations.  
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able 1: R
esults of the survey divided for the different geographic areas. 
 
 
T
otal (#128) 
%
 (#) 
N
orth (#33) 
%
 (#) 
C
enter (#43) 
%
 (#) 
South (#52) 
%
 (#) 
1) D
o you directly prescribe/suggest statins in your H
IV
 patients w
hen appropriate? 
 Y
es 
89 (114) 
91 (30) 
95  (41) 
83  (43) 
 N
o, I refer m
y patients to other specialists if I think they need statins 
11 (14) 
9  (3) 
5    (2) 
17  (9) 
 N
o, I do not treat cardiovascular risk in m
y H
IV
 patients 
0 
0 
0 
0 
 
 
 
 
 
2) D
o you follow
 any guideline to evaluate the opportunity of prescribing statins in your H
IV
 patients? 
 Y
es 
73 (94) 
70 (23) 
77 (33) 
73 (38) 
 N
o 
27 (34) 
30 (10) 
23 (10) 
27 (14) 
 
 
 
 
 
3) If yes, w
hich one?*  
 
 
 
 
 EA
C
S  H
IV
 
35  (37) 
44 (11) 
42 (16) 
24 (10) 
 Italian H
IV
 G
uidelines 
46 (48) 
36 (9) 
26 (10) 
69  (29) 
 A
C
C
/A
H
A
 2013 
19 (20) 
20 (5) 
32 (12) 
7   (3) 
 
 
 
 
 
4) If not, how
 do you evaluate the opportunity of prescribing statins in your H
IV
 patients?* 
 B
ased on total cholesterol 
9 (5) 
13 (3) 
7  (1) 
14 (3) 
 B
ased on LD
L cholesterol 
36 (21) 
33 (8) 
40  (6) 
34 (7) 
 B
ased on estim
ated cardiovascular risk 
34 (20) 
29 (7) 
33 (5) 
38 (8) 
 In the presence of co-m
orbidity (e.g., diabetes) 
21 (12) 
25 (6) 
20 (3) 
14 (3) 
 
 
 
 
 
5) D
o you directly prescribe/suggest aspirin in your H
IV
 patients w
hen appropriate? 
 Y
es 
43 (55) 
61 (20) 
53 (23) 
23 (12) 
 N
o, I refer m
y patients to other specialists if I think they need aspirin 
57 (73) 
39 (13) 
47 (20) 
77 (40) 
 N
o, I do not treat cardiovascular risk in m
y H
IV
 patients 
0 
0 
0 
0 
 
 
 
 
 
6) D
o you utilize any score to calculate the cardiovascular risk of your H
IV
 patients? 
 Y
es 
58 (74) 
73 (24) 
67 (29) 
40 (21) 
  
 N
o, I evaluate the risk factors  (blood pressure, cholesterol, sm
oke, diabetes) w
ithout the use of 
scores 
42 (54) 
27 (9) 
33 (14) 
60 (31) 
N
o, I do not evaluate cardiovascular risk factors at all 
0 
0 
0 
0 
 
 
 
 
 
7) If yes, w
hich one? *  
 Fram
ingham
  Score 
71 (69) 
71 (22) 
65 (26) 
81  (21) 
 A
SC
V
D
 
13 (12) 
16 (5) 
12 (5) 
8   (2) 
 D
A
D
 
12 (12) 
3  (1) 
20 (8) 
11  (3) 
 Progetto C
uore 
4  (4) 
10 (3) 
3 (1) 
0 
 
 
 
 
 
8) D
o you prescribe statins in patients w
ith subclinical atherosclerosis diagnosed w
ith C
A
C
 or IM
T? 
 Y
es  
50 (64) 
36 (12) 
44 (19) 
38  (20) 
 N
o 
50 (64) 
64 (21) 
56 (24) 
62  (32) 
 
 
 
 
 
9) B
efore prescribing a statin do you evaluate the drug-drug interactions w
ith the antiretroviral therapy? 
 Y
es 
97 (124) 
91 (30) 
98 (42) 
100  (52) 
 N
o 
3  (4) 
9  (3) 
2  (1) 
0 
 
 
 
 
 
10) In case of drug-drug interactions do you  
 A
bandon the statin therapy? 
13 (17) 
21 (7) 
19 (8) 
4   (2) 
 C
hange the statin? 
49 (59) 
43 (14) 
46 (20) 
50  (25) 
 C
onsult a cardiologist? 
38 (52) 
36  (12) 
45 (15) 
46  (25) 
 *=m
ultiple answ
ers adm
itted  
